about
Current Status and Future Projections of Breast Cancer in AsiaImproving access to high-cost cancer drugs in Latin America: Much to be done.Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model.Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer.Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyAromatase inhibitors for chemoprevention.Advances in adjuvant hormonal therapy for postmenopausal women.Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.Suitable trial designs and cohorts for preventive breast cancer agents.Breast cancer in China.Prolactin and breast cancer: The need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: A review.Progress and remaining challenges for cancer control in Latin America and the Caribbean.Cervical cancer control in Latin America: A call to action.Current and emerging therapies of HER2-positive metastatic breast cancer.Epidemiology and pathophysiology of pregnancy-associated breast cancer: A review.Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.Planning cancer control in Latin America and the Caribbean.Challenges to effective cancer control in China, India, and Russia.Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma.Prevention strategies with aromatase inhibitors.Evaluation of diagnostic and treatment approaches towards acute dyspnea in a palliative care setting among medical students at the University of Vienna.Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.Barriers to Primary Debulking Surgery for Advanced Ovarian Cancer in Latin America.Competing risks in low-risk breast cancer.A survey among oncologists on measures needed to improve cancer care.Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor.Endometrial Cancer in Brazil: Preparing for the Rising Incidence
P50
Q26753883-B7373452-26B1-4919-A6A8-6DDD8F0C8329Q30235988-5351755B-2BF4-4AF3-9629-0E0F76B6A342Q33271204-98BD3390-D5B4-47D5-804E-23361CBD7C18Q34419312-D274D23B-D344-415E-BAD3-263F230D54E2Q34529725-508EC937-53D8-4848-994E-4D3BDE08A417Q35580011-74A57D70-43BB-4334-A737-215123F85535Q35612327-E1DCDB2F-4203-4762-ABD5-10D7934611CAQ36065501-5E6F9B1E-4EFE-4496-879E-7E85A8EE8A00Q38145803-1BC78F8D-5890-4ACA-8F20-D19AA171D79CQ38150222-62A85FF7-433D-49E2-8BE8-976EC301CF6CQ38215704-78835E93-5B11-449A-A646-506F4C9724ECQ38604789-7B32DAA9-694B-40C1-B4E3-CB187B0E3FBCQ38621708-4B1FE21D-F232-4554-9E28-039B2317194EQ38670183-47CB2E1E-1B95-495B-856A-0951B7595148Q38831200-BF6CE8E0-7E6D-4C52-963A-69AB05C662A1Q39450822-711F5251-805E-416F-BFB3-2A20997DF36AQ40038429-02C65C2A-6DA7-487B-8B49-CED174DDE54FQ40108098-31FD5EF6-3D1D-4613-9F3B-20D210AF4572Q40184512-A33B7408-F1D6-42A2-97F2-DE3CBD1D8399Q43999296-38BE21A8-A585-4895-9B69-E5D431AF7EF5Q44735727-AD5E7A31-DD58-4DA8-A0E8-C98AA6FDA693Q45930729-68F83ABC-61F7-410F-A55D-70E8AEC79C50Q47556532-5F1FCB5D-A4C6-46F0-B16B-2E43BF84628DQ50248573-13336653-3A75-4F52-853F-8C2E2B705DCBQ50955171-0BCE3700-2CED-4DEF-B4D3-2BAAC030805AQ53233835-E4B3A238-62B6-43AD-92B9-569EE0A5BBF9Q53558683-87922162-19EA-42D3-AB31-482C37A56757Q57807248-710428AD-BFFF-4374-8D15-A3A6323E1357
P50
name
Kathrin Strasser-Weippl
@ast
Kathrin Strasser-Weippl
@en
Kathrin Strasser-Weippl
@nl
type
label
Kathrin Strasser-Weippl
@ast
Kathrin Strasser-Weippl
@en
Kathrin Strasser-Weippl
@nl
prefLabel
Kathrin Strasser-Weippl
@ast
Kathrin Strasser-Weippl
@en
Kathrin Strasser-Weippl
@nl